CSL Behring pays $91M upfront for early stage gene therapy – BioPharma Dive
|
CSL Behring pays $91M upfront for early stage gene therapy
BioPharma Dive CSL Behring has bought out Calimmune, a Tucson-based stem cell gene therapy biotech, for a $91 million upfront payment. The deal gives CSL Behring access to Calimmune's stem cell platforms Select+ and Cytegrity, as well as its CAL-H product candidate, … |
